October 7, 2019 06:39 AM EDTUpdated 09:15 AM

Differin maker Galderma wins FDA approval for a new retinoid for acne

Natalie Grover

Reporter

Data suggest that in 2016 the burden of acne vulgaris — the chronic inflammatory skin disease — ballooned to roughly $3 billion in healthcare costs and …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Differin maker Galderma wins FDA approval for a new retinoid for acne

Natalie Grover

Reporter

Sign up to read this article for free.

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

Roche no longer wants to be where ‘DNA sequencing goes to die’

Trump’s HHS defends drug price negotiations in Novartis suit

Trump’s picks for NIH, CMS say they’ll unload industry investments

First meeting of CDC vaccine advisors in the Kennedy era is postponed

How Keymed steered the China-to-US NewCo model in biotech

Trusted protection: Why the current meningococcal vaccination schedule shouldn’t change without strong evidence

Dif­ferin mak­er Gal­der­ma wins FDA ap­proval for a new retinoid for ac­ne

Reporter

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

Differin maker Galderma wins FDA approval for a new retinoid for acne